David Hung

Biography

David Hung joined Axovant as Chief Executive Officer and a member of the Board in April 2017. Dr. Hung founded Medivation in 2003 and served as President and Chief Executive Officer through its acquisition by Pfizer in 2016. During his tenure as CEO, Medivation achieved FDA approval for XTANDI® (enzalutamide) as a treatment for patients with metastatic castration-resistant prostate cancer. XTANDI® is the top-selling prostate cancer treatment globally. Prior to Medivation, Dr. Hung served as President and Chief Executive Officer at ProDuct Health, Inc., from 1999 until its acquisition by Cytyc Corporation in 2001, and was Vice President of New Projects as well as Lead Discovery and Development at Chiron Corporation. Dr. Hung completed clinical fellowships in hematology, oncology, and transfusion medicine as well as basic science research fellowships in molecular biology at the University of California, San Francisco, School of Medicine. Dr. Hung holds an M.D. Alpha Omega Alpha from the University of California, San Francisco, School of Medicine, and an A.B. in Biology summa cum laude from Harvard College.  

Research Interest

 Molecular Biology and Hematology